The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models - Durant, S. T., Zheng, L., Wang, Y., Chen, K., Zhang, L., Zhang, T., Yang, Z., Riches, L., Trinidad, A. G., Fok, J. H. L., Hunt, T., Pike, K. G., Wilson, J., Smith, A., Colclough, N., Reddy, V. P., Sykes, A., Janefeldt, A., Johnström, P., Varnäs, K., Takano, A., Ling, S., Orme, J., Stott, J., Roberts, C., Barrett, I., Jones, G., Roudier, M., Pierce, A., Allen, J., Kahn, J., Sule, A., Karlin, J., Cronin, A., Chapman, M., Valerie, K., Illingworth, R., Pass, M. (American Association for the Advancement of Science (AAAS), 2018)
6289333